Revolution

AI models will create whole new classes of therapies, by design

Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more  

As regulatory hurdles push early-stage trials out of the U.S., three things FDA can do to bring them back

Advice for CEOs and CFOs as they navigate the year ahead

Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem

BioCentury’s final Public Equity Report of the year tallies up fundraising activity

Longtime CDER staffer led ‘regulatory revolution’

BioNTech gearing up to advance BNT327 to Phase III for triple-negative breast cancer after promising Phase II survival data

Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more

In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial